COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours VALNEVA : Rapport Semestriel 2025
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours Focus on sustainable profitability: Komax Group reduces costs considerably Komax Group achieves sustainable profitability by reducing costs considerably amid market challenges. Positive EBIT and cost savings of CHF 25 million confirmed in 2025 half-year results Market Challenges EBIT Cost Reduction Komax Group Sustainable Profitability
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours Sonova expands Infinio range and enters new market segment with Phonak’s smallest and first rechargeable in-the-ear hearing aid Sonova expands Infinio range with Phonak's smallest rechargeable in-the-ear hearing aid, Phonak Virto R Infinio. The launch marks an important step in entering the market segment Sonova Hearing Aid Phonak Infinio Rechargeable
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours LLB successfully concludes share repurchase programme Liechtensteinische Landesbank AG successfully concludes share repurchase programme holding 1.4% of share capital Share Repurchase Capital Structure Liechtensteinische Landesbank LLB Treasury Management
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours SCHOTT Pharma delivers solid final third-quarter results SCHOTT Pharma reports solid Q3 2025 results with 1% revenue growth, 32.4% EBITDA margin, and strategic innovations Revenue Growth EBITDA Margin SCHOTT Pharma Innovations Q3 2025 Results
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates Valneva SE reports €97.6 million revenues in H1 2025, confirms 2025 financial outlook. Highlights financial results, R&D progress, and commercial updates Revenues Financial Results Valneva SE R&D Progress 2025 Outlook Commercial Updates
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 07:00, il y a 7 mois 22 jours Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités. Chiffre d’affaires en hausse, trésorerie solide et perspectives confirmées. Détails disponibles sur le site de la société Résultats Financiers Perspectives Valneva Vaccins Premier Semestre 2025
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 06:55, il y a 7 mois 22 jours PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range PolyPeptide Group reports +24% revenue growth in H1 2025, revises full-year guidance towards upper range. EBITDA improved to EUR 4.4 million, major investments in capacity expansion projects EBITDA Revenue Growth Capacity Expansion PolyPeptide Group Full-year Guidance
COMMUNIQUÉ DE PRESSE publié le 12/08/2025 à 06:55, il y a 7 mois 22 jours TAG Immobilien AG reports strong growth in FFO I and EPRA NTA in the first half of 2025; positive valuation results in Germany and Poland; further decline in LTV TAG Immobilien AG reports strong growth in FFO I and EPRA NTA in the first half of 2025; positive valuation results in Germany and Poland; further decline in LTV TAG Immobilien AG EPRA NTA LTV FFO I Valuation Results
Publié le 02/04/2026 à 18:39, il y a 13 heures 56 minutes Mersen : Déclaration des transactions sur actions propres
Publié le 02/04/2026 à 18:30, il y a 14 heures 6 minutes Thales met à disposition son Document d’Enregistrement Universel 2025
Publié le 02/04/2026 à 18:30, il y a 14 heures 6 minutes Thales makes available its Universal Registration Document 2025
Publié le 02/04/2026 à 18:22, il y a 14 heures 13 minutes TF1 - Déclaration mensuelle des actions et droits de vote - Mars 2026
Publié le 02/04/2026 à 22:00, il y a 10 heures 36 minutes Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Publié le 02/04/2026 à 18:32, il y a 14 heures 4 minutes Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Publié le 02/04/2026 à 15:00, il y a 17 heures 36 minutes Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Publié le 02/04/2026 à 14:40, il y a 17 heures 56 minutes Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Publié le 02/04/2026 à 14:30, il y a 18 heures 6 minutes Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Publié le 03/04/2026 à 08:10, il y a 25 minutes UnionPay Launches Agentic Payment Open Protocol Framework: Building an Open, Trusted Smart Payment Ecosystem
Publié le 03/04/2026 à 07:05, il y a 1 heure 30 minutes JINRO Unveils JINRO MELON LIMITED EDITION: A Premium Fusion of Sweetness and Sophistication
Publié le 03/04/2026 à 06:59, il y a 1 heure 36 minutes Aperam publishes Convening Notice for Annual General Meeting of shareholders
Publié le 03/04/2026 à 06:59, il y a 1 heure 36 minutes Aperam publie sa Convocation à son Assemblée Générale Annuelle des actionnaires
Publié le 02/04/2026 à 23:55, il y a 8 heures 40 minutes Brazil's second-crop corn can provide a low-carbon pathway for Sustainable Aviation Fuel (SAF)